First-pass metabolism, rapid systemic clearance leading to short-lived epidermal exposure – why oral supplementation falls short.
Oral nicotinamide has demonstrated safety and modest benefit, but its effectiveness in skin is constrained by rapid systemic clearance, first-pass metabolism, and short-lived epidermal exposure.
The skin — the primary site of UV damage — receives only brief and diluted exposure following oral dosing, limiting sustained biological impact.
Topical therapy treats the problem where it occurs
Direct skin delivery
Bypasses first-pass metabolism.
Sustained exposure
Therapeutic epidermal concentrations maintained for 12 hours, not 1-2 hours.
Reduced (minimal) systemic burden
Targeted delivery – no increase in nicotinamide blood levels over natural baseline
Routine-compatible
Integrates naturally into daily skin care behaviour.
Topical therapy enables consistent restoration of cellular energy (NAD⁺ / ATP), DNA repair capacity, immune competence, and barrier integrity — outcomes oral supplementation struggles to sustain.